Prevention of Early Alzheimer's Disease by Erinacine A-EnrichedHericium erinaceusMycelia Pilot Double-Blind Placebo-Controlled Study

doi:10.3389/fnagi.2020.00155

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24681

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24681

Title:	Prevention of Early Alzheimer's Disease by Erinacine A-EnrichedHericium erinaceusMycelia Pilot Double-Blind Placebo-Controlled Study
Authors:	Li, IC;Chang, HH;Lin, CH;Chen, WP;Lu, TH;Lee, LY;Chen, YW;Chen, YP;Chen, CC;Lin, DPC
Keywords:	erinacine A-enrichedH;erinaceusmycelia;Alzheimer's disease;pilot study;prevention;magnetic resonance imaging
Date:	2020
Issue Date:	2022-08-09T08:06:17Z (UTC)
Publisher:	FRONTIERS MEDIA SA
ISSN:	1663-4365
Abstract:	Objective To investigate the efficacy and safety of threeH. erinaceusmycelia (EAHE) capsules (350 mg/capsule; containing 5 mg/g erinacine A active ingredient) per day for the treatment of patients with mild Alzheimer's Disease (AD). Methods This study comprised a 3-week no-drug screening period, followed by a 49-week double-blind treatment period with 2-parallel groups in which eligible patients were randomized to either three 5 mg/g EAHE mycelia capsules per day or identical appearing placebo capsules. Cognitive assessments, ophthalmic examinations, biomarker collection, and neuroimaging were followed throughout the study period. Results After 49 weeks of EAHE intervention, a significant decrease in Cognitive Abilities Screening Instrument score was noted in the placebo group, a significant improvement in Mini-Mental State Examination score was observed in the EAHE group and a significant Instrumental Activities of Daily Living score difference were found between the two groups. In addition, EAHE group achieved a significantly better contrast sensitivity when compared to the placebo group. Moreover, only the placebo group observed significantly lowered biomarkers such as calcium, albumin, apolipoprotein E4, hemoglobin, and brain-derived neurotrophic factor and significantly elevated alpha1-antichymotrypsin and amyloid-beta peptide 1-40 over the study period. Using diffusion tensor imaging, the mean apparent diffusion coefficient (ADC) values from the arcuate fasciculus region in the dominant hemisphere significantly increased in the placebo group while no significant difference was found in the EAHE group in comparison to their baselines. Moreover, ADC values from the parahippocampal cingulum region in the dominant hemisphere significantly decreased in the EAHE group whereas no significant difference was found in the placebo group when compared to their baselines. Lastly, except for four subjects who dropped out of the study due to abdominal discomfort, nausea, and skin rash, no other adverse events were reported. Conclusion Three 350 mg/g EAHE capsules intervention for 49 weeks demonstrated higher CASI, MMSE, and IADL scores and achieved a better contrast sensitivity in patients with mild AD when compared to the placebo group, suggesting that EAHE is safe, well-tolerated, and may be important in achieving neurocognitive benefits.
URI:	http://dx.doi.org/10.3389/fnagi.2020.00155 https://www.webofscience.com/wos/woscc/full-record/WOS:000542976300001 https://ir.csmu.edu.tw:8080/handle/310902500/24681
Relation:	FRONTIERS IN AGING NEUROSCIENCE ,2020 ,v12
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	191	View/Open

Loading...